Meda's NDA for New Formulation of Allergy Drug Accepted By FDA
Posted on: Tuesday, 28 October 2008, 06:00 CDT
Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation.
Anders Lonner, CEO of Meda, said: "This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation it could also mean better compliance for patients. The product would contribute significantly to Meda's allergy franchise."
Meda has completed six Phase III studies and a long-term safety study, involving more than 1,600 patients in total. In these clinical studies, the product demonstrated improvement in nasal symptom relief scores in patients with seasonal and perennial allergic rhinitis, and was well tolerated, said Meda.
Source: Datamonitor
Related Articles
- New Data On Highly Effective Treatment For Chronic Rhinosinusitis With Nasal Polyps
- Meda Acquires Product Portfolio From Roche
- Meda: Strategic Partnership With Almirall and Full-Year Forecast for 2006
- ADDING and REPLACING FDA Approves Merck's GARDASIL(R), the World's First and Only Cervical Cancer Vaccine; GARDASIL Prevents Cervical Cancer, Precancerous and Low-Grade Lesions and Genital Warts Caused By HPV Types 6, 11, 16 and 18
- Azelastine Nasal Spray and Desloratadine Tablets in Pollen-Induced Seasonal Allergic Rhinitis: a Pharmacodynamic Study of Onset of Action and Efficacy
- FDA Approves EMEND(R) (Aprepitant), in Combination With Other Antiemetics, for the Prevention of Nausea and Vomiting in Cancer Patients Undergoing Moderately Emetogenic Chemotherapy
- New Analysis in Patients With Type 2 Diabetes From Trial With VYTORIN-TM- -Ezetimibe/Simvastatin- Presented at ADA; Consistent With Overall Study Which Showed Superior LDL Cholesterol Reduction With VYTORIN Versus Lipitor
- Article Supports Use of Diagnostic Blood Tests for Allergies; Evidence Helps Boost Low Accuracy of Diagnosis Rates and Improve Patient Care
- Study of Breast Cancer Patients Showed Regimen Including EMEND-R- -Aprepitant- Prevented Nausea and Vomiting After Chemotherapy in More Patients Than a Standard Regimen
- Nasal Polyposis in the Laryngectomee
 |
 |
User Comments (0)
RSS Feeds